GLP-1 Medicines: The Metabolic Revolution Reshaping Modern Medicine

 

 

What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) is a hormone produced naturally in the gut in response to
food intake. It signals the pancreas to release insulin, suppresses glucagon (which raises
blood sugar), slows gastric emptying, and crucially — signals the brain's hypothalamus to
reduce appetite and induce satiety. GLP-1 receptor agonists (GLP-1 RAs) are drugs
engineered to mimic and amplify this hormone's effects, with dramatically longer half-lives
than the natural hormone.
The two agents that have defined this class in the modern era are semaglutide
(Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly). While
semaglutide is a pure GLP-1 agonist, tirzepatide is a dual agonist — targeting both GLP-1
and GIP (glucose-dependent insulinotropic polypeptide) receptors, achieving synergistic
metabolic effects through simultaneous activation of two hormonal pathways found in the
brain, fat cells, and pancreatic cells.

 

Weight Loss Efficacy: What the Data Shows

The clinical evidence for GLP-1 RAs in obesity is now among the most robust in
pharmaceutical history:
Liraglutide (3mg daily): ~5% placebo-corrected weight loss · FDA approved 2014
Semaglutide 2.4mg (weekly): ~12% placebo-corrected weight loss · 50.5% of participants lost
≥15% of body weight
Tirzepatide 15mg (weekly): ~18% placebo-corrected weight loss · 56.7% lost ≥20% body
weight · 36% lost ≥25%
A 2025 Cochrane systematic review — requested by the WHO to guide global obesity
treatment recommendations — confirmed that all three agents produced clinically
meaningful weight loss over 12–24 months. Tirzepatide produced approximately 16% body
weight reduction at 12–18 months, while semaglutide achieved approximately 11% over
24–68 weeks.
In December 2025, the FDA approved an oral formulation of semaglutide, demonstrating
approximately 13.7% average weight loss over 64 weeks — nearly equivalent to the
injectable form. This marks a significant step toward wider patient access.
Beyond Weight Loss: The Expanding Evidence Base
The most scientifically compelling aspect of GLP-1 research in 2025 is the accumulating
evidence for benefits extending far beyond glucose control and weight management:
Cardiovascular Protection
A 2025 landmark head-to-head study from Mass General Brigham, published in Nature
Medicine and presented at the American Heart Association Scientific Sessions, compared
cardiovascular outcomes in nearly one million adults. Semaglutide reduced risk of stroke and
heart attack by 18% versus sitagliptin (a diabetes drug with neutral cardiovascular effects).
Tirzepatide lowered risk of stroke, heart attack, and death by 13%. In the EU, the EMA
approved semaglutide in September 2025 as the first stroke management therapy, based on
the phase 3 SOUL trial of nearly 10,000 patients.

 

Sleep Apnea

 

In a historic 2024–2025 milestone, the FDA approved tirzepatide (Zepbound) as the first
medication approved for obstructive sleep apnea (OSA). Phase 3 trials demonstrated a
reduction in the Apnea-Hypopnea Index by 23.8 events per hour compared to placebo,
attributed to reductions in upper airway adiposity including tongue fat.

 

Liver Disease (MASH/NAFLD)

Both semaglutide and tirzepatide have shown significant reductions in hepatic steatosis and
liver inflammation markers in patients with metabolic dysfunction-associated steatotic liver
disease (MASLD/MASH) — a condition with very few effective pharmacologic treatments —
making GLP-1 RAs promising candidates for this major unmet clinical need.

 

Neurological Conditions

Emerging research (2025) has identified GLP-1 receptors in the brain's reward circuits and
explored GLP-1 RAs for depression, Parkinson's disease, and Alzheimer's disease. Trials
including OxSENSE are investigating semaglutide's effects on cognition, reward processing,
and neuroinflammation. GLP-1 agents are also being studied for idiopathic intracranial
hypertension.

 

Important Considerations and Limitations

GLP-1 RAs are not without concerns that the research community is actively studying:
▸ Gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) affect 20–40% of
patients, typically mild-to-moderate and dose-dependent
▸ Lean mass loss: 25–45% of total weight lost may come from lean body mass, raising
concerns about muscle preservation, particularly in older patients
▸ Weight regain: stopping treatment leads to significant weight regain. Real-world data
shows that only 14% of patients remain on Wegovy after 3 years
▸ Rare risks: gallbladder disorders, rare cases of pancreatitis; safety in thyroid cancer-
prone patients under monitoring
▸ A 2025 Nature study of 27,885 participants identified genetic variants in GLP1R and
GIPR associated with both efficacy and side effects — pointing toward a precision medicine
future where genetic profiling guides drug selection

 

The Future: Triple Agonists and Beyond

Research is already moving beyond dual agonism. Retatrutide, a triple agonist targeting
GLP-1, GIP, and glucagon receptors, is showing even greater weight loss in early phase
trials. A 2025 UAB presentation described a five-receptor agonist combining GLP-1, GIP,
and PPAR nuclear hormone receptors — theoretically targeting multiple metabolic pathways
simultaneously. The GLP-1 revolution is accelerating.

 

References

[1] Krüger N et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2
diabetes in clinical practice. Nature Medicine. 2025. doi:10.1038/s41591-025-04102-x
[2] Guo H et al. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a
model-based meta-analysis. Obes Pillars. 2025;13:100162.
[3] Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM.
2023;389:2221-2232. doi:10.1056/NEJMoa2307563
[4] Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387:205-216.
doi:10.1056/NEJMoa2206038
[5] Rodriguez PJ et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity.
JAMA Internal Medicine. 2024;184:1056–1064.
[6] Rubino DM et al. Semaglutide 2.4 mg in Adults with Overweight or Obesity and Type 2 Diabetes.
JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619.
[7] Nature (2026). Genetic predictors of GLP1 receptor agonist weight loss and side effects.
doi:10.1038/s41586-026-10330-z